Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment

Ver todos los episodios